Actinogen anticipates final topline efficacy and safety results for the full 36-week treatment period in November 2026.

Researchers report the first autopsy-confirmed case of Alzheimer's disease following suspected medical transmission, but experts say definitive causation may remain elusive.

Early results from a small clinical trial at Changi General Hospital suggest the technique could lead to improvements in ...

Leqembi efficacy doubts in APOE4 subgroups raise regulatory and commercial risks for Eisai and Biogen; see real-world data ...

Compared with standard-dose shots, high-dose flu shots were associated with a lower risk for Alzheimer's dementia in the ...

The idea that two conditions at opposite ends of life might be biologically linked is beginning to upend long-standing ...

Campbell: Welcome to "Beyond Diagnosis," where we talk with doctors about talking with patients. I'm your host, Glenn ...

The origins of Alzheimer's remain contentious, but a new study suggests the disease may emerge as two key proteins compete ...

Doctors say that the number of people with Alzheimer’s disease could potentially triple within the next 25 years. Families of ...

A new study suggests that a hormone therapy harvested from human corpses may be linked to a rare, controversial form of ...

In Alzheimer’s disease, brain damage is often linked to a mix of problems, including beta-amyloid buildup, tau pathology, ...